Temozolomide

For research use only.

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856,TMZ

76 publications

Temozolomide Chemical Structure

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 62 In stock
EUR 68 In stock
EUR 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Temozolomide has been cited by 76 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELYRnI1QCCq MULJR|UxRTF|OT6yNQKBkcLz4pEJOU46PSEQvF2= MUSyOVk3ODJ6Mh?=
KellyCis83 NWn4Z|RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XPdVQ5KGh? NGP2W3dKSzVyPUK1NU4xOOLCidMx5qCKOTVwN{Wg{txO MWWyOVk3ODJ6Mh?=
SK-N-AS M3\Bfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrUUXU1QCCq MmW1TWM2OD1{MkeuO|DjiIoEsfMAjVIzNjF3IN88US=> NEPOUoIzPTl4MEK4Ni=>
SK-N-ASCis24 M4TRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDYT4w1QCCq NY\1d|JqUUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? MnP6NlU6PjB{OEK=
CHP-212 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zhbVQ5KGh? MmPSTWM2OD15Lkm35qCKyrIkgJmwMlY6KM7:TR?= M{TsflI2QTZyMkiy
CHP-212Cis100 NVy0OHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnlWpV[PDhiaB?= M{HJ[2lEPTB;OT61OgKBkcLz4pEJNE45QCEQvF2= NHXHcY4zPTl4MEK4Ni=>
U87  MV;GeY5kfGmxbjDBd5NigQ>? NGfoUJYyODBizszN MlzVNlQuPzJiaB?= MXnpcoR2[2W|IFTjVlEh\XiycnXzd4lwdg>? MUSyOVgxQDh4OB?=
LN229 NECxV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\GWWwxNTVyIN88US=> NEXXWINKSzVyPUG2JO69VQ>? NEjvbHkzPTd3MEK3Ny=>
TR-LN229 M1HNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKcXQxNTVyIN88US=> NG\2UIJKSzVyPUe3JO69VQ>? NUH5UFV4OjV5NUCyO|M>
U87  MUfBdI9xfG:|aYOgRZN{[Xl? MWWw5qCUOjBy4pEJxtVO M3\kWlI1KGh? MULlcohidmOnczDDVUBqdmS3Y3XkJIFxd3C2b4Ppdy=> Ml;XNlU3QDF4Nki=
U251MG MlvxRZBweHSxc3nzJGF{e2G7 MmTjNVAxyqEQvF2= M1HMXFQ5KGh? NWfGNItTWEKV MljtbY5lfWOnczDhdI9xfG:|aYO= NF\GXlYzPTZ6MES2OC=>
U87MG MWrBdI9xfG:|aYOgRZN{[Xl? M2Dsc|ExOMLizszN MorNOFghcA>? M3LmNXBDWw>? MXHpcoR2[2W|IHHwc5B1d3Orcx?= M3vPUFI2PjhyNE[0
U87 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDwbXA2OC1|NUCg{txO M3HnV|Q5yqCqwrC= MV;pcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> Mn7iNlU2PTR{MkO=
U118  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fXblUxNTN3MDFOwG0> M1PCbFQ5yqCqwrC= MljYbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> Ml;PNlU2PTR{MkO=
U87 M3XnfmZ2dmO2aX;uJGF{e2G7 M2TCOlI2OC9|NUCg{txO NFz1OYI1QMLiaNMg MlzO[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm MoLSNlU2PTR{MkO=
U118  NUTOVYx6TnWwY4Tpc44hSXO|YYm= NX7yZodlOjVyL{O1NEDPxE1? MVe0POKhcMLi M{SyNIVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? MkLSNlU2PTR{MkO=
U87 M1vabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfJNlUxNzN3MDFOwG0> M3zqW|Q5yqCqwrC= NWPldWU4cW6lcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHzzJIlvKFNiYX7kJGczN04EoHPveJJm[XSnZDD3bZRpKFSPWB?= MlPJNlU2PTR{MkO=
A375 NYj3PYs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXPOFjDqGkEoB?= NV7aZm46UUN3ME2yOlUh|ryP NXTVTJBvOjV3MkS1OVI>
A2058 M{HCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVO0POKhcMLi NHHqW5dKSzVyPUGyJO69VQ>? NX6yWGVGOjV3MkS1OVI>
M238 M{DXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z5bVQ5yqCqwrC= MkXOTWM2OD12MDFOwG0> M{W3S|I2PTJ2NUWy
M249 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW0POKhcMLi NYDQTVlJUUN3ME2yOVQh|ryP NYfKRVFJOjV3MkS1OVI>
M21 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG0POKhcMLi M1vxeWlEPTB;MkKxJO69VQ>? MmHCNlU2OjR3NUK=
U251 NV;aVWt5S3m2b4TvfIl1gSCDc4PhfS=> NVXGV3pnOjBizszNxsA> MnT6OFjDqGkEoB?= M1PK[pJm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS= NI[1coUzPTR|NEO4NS=>
LN229 NFi3XJJEgXSxdH;4bZR6KEG|c3H5 NVLhZWszOjBizszNxsA> NFTtT2E1QMLiaNMg MnvrdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= NEC1NXIzPTR|NEO4NS=>
U373MG-LUC NGLlNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2XotuPzJiaB?= MWLJR|UxRjZyMDFOwG0> M1TZOFI2PDNzOUWz
U87  MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r0TlI2NTJyMDFOwG0> MYO0POKhcMLi MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF6zRZUzPTRyMEe0OS=>
U251 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O4VlI2NTJyMDFOwG0> MmS5OFjDqGkEoB?= M1:x[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2rZ[FI2PDByN{S1
U251 NETYO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED2b|cyODBvNECwJO69VQ>? MV:3Nk86PiCq NY\NOJVRfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg MkXVNlU{PzV{N{G=
U373 NHLaWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvzZ|QyODBvNECwJO69VQ>? MWi3Nk86PiCq NGHXTGN1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= MUSyOVM4PTJ5MR?=
U343 M1:yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S1OVExOC12MECg{txO NU\DNVZ7PzJxOU[gbC=> M{L4V5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MnWxNlU{PzV{N{G=
U87MG-luc2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPWNVAxNTRyMDFOwG0> M4L0XlczNzl4IHi= MWj0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NYHqVGROOjV|N{WyO|E>
U87 NGDNXIJHfW6ldHnvckBCe3OjeR?= MXKyNFAh|ryP MYG0PEBp NVr4cW1kcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= M1jGe|I2OzN5N{Kx
U251 M2DDW2Z2dmO2aX;uJGF{e2G7 NWHZR4pLOjByIN88US=> NGTkZnE1QCCq M2nEOolv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MmPYNlU{Ozd5MkG=
A172 NX7QSno6TnWwY4Tpc44hSXO|YYm= MYWyNFAh|ryP MXG0PEBp NVeyN2dZcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= MV6yOVM{Pzd{MR?=
U251 MonOSpVv[3Srb36gRZN{[Xl? M13xfVIxOCEQvF2= MVS0PEBp MXjpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz M1ziUVI2OzN5N{Kx
A172 M4rDO2Z2dmO2aX;uJGF{e2G7 NYfEcoVFOjByIN88US=> NV7mWGVbPDhiaB?= MoHUbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MonaNlU{Ozd5MkG=
U87 NFvIZ4ZHfW6ldHnvckBCe3OjeR?= MYCyNFAh|ryP NXz4dFVUOjRxN{KvNVIxKGh? M2XwcIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MnjHNlU{Ozd5MkG=
U251 NUK0bYNTTnWwY4Tpc44hSXO|YYm= NEXybmYzODBizszN MnHkNlQwPzJxMUKwJIg> MUDpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> MmH2NlU{Ozd5MkG=
A172 MoDESpVv[3Srb36gRZN{[Xl? M4r0TFIxOCEQvF2= MWiyOE84Oi9zMkCgbC=> MmTwbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 NWKwenpkOjV|M{e3NlE>
SNB19V M3TzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXQV4g4KGR? M3;RdGROW09? MYXHTVUxRTN3LkhCtVEzKM7:TR?= MX[yOVI4PzR2MR?=
SNB19M NHvRd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3JIQ> M4rKfGROW09? MXLHTVUxRTR4OT65xtE5QCEQvF2= NYH1N|h3OjV{N{e0OFE>
SNB19VR NX61fVluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjtPVFRPyCm MYfEUXNQ NVizbZhxT0l3ME2yPFAvOsLzMUig{txO NYHudoFuOjV{N{e0OFE>
U373V NVrIPYsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PEO|ch\A>? MUDEUXNQ Ml33S2k2OD14OD6wxtE{OiEQvF2= MUKyOVI4PzR2MR?=
U373M NFnoSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm0RpM4KGR? MmDZSG1UVw>? NFjkOJFIUTVyPUO2PE44yrF6NjFOwG0> NID5ZogzPTJ5N{S0NS=>
U373VR NXnhRo1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljvO{Bl NU\IVnZpTE2VTx?= NWixSIFMT0l3ME2yPFgvQMLzM{Og{txO MoTlNlUzPzd2NEG=
U87MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vb|ch\A>? NHexRlVFVVOR MlzmS2k2OD1|OD6zxtEzOCEQvF2= M2TnW|I2Ojd5NESx
HCT116 NVXX[YhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi1fWh[PyCm NVe2[YhRTE2VTx?= NVnMOG8{T0l3ME21O|kvQcLzM{Kg{txO MnniNlUzPzd2NEG=
DLD1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[3JIQ> MXPEUXNQ MYjHTVUxRTVyMT60xtE6OyEQvF2= M4W1OlI2Ojd5NESx
MRC5 M3XIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF63TI84KGR? MUDEUXNQ NUHE[GJwT0l3ME20OFkvPMLzODFOwG0> M3r0U|I2Ojd5NESx
SNB19V  NUHvT4tKTnWwY4Tpc44hSXO|YYm= MUWxNFAh|ryPwrDUUXo> NE\sNWoxNTd{IHi= MkD3bY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> MUmyOVI4PzR2MR?=
T98G  M1K3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG1M|ExNzF3IN88US=> NIjJc|QzPMLiaB?= NFzNeoRqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> M4XDb|I2OjZ{OU[x
U251  NViyPIFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWO1M|ExNzF3IN88US=> NHfLRY8zPMLiaB?= MWTpcoR2[2W|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?= MUWyOVI3Ojl4MR?=
T98G  NE\Ue|dHfW6ldHnvckBCe3OjeR?= Mly1NVUh|ryP NYPS[YR1OjUEoHi= NUHtUFdOcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz M1v6W|I2OjZ{OU[x
U251  NV\NUGt4TnWwY4Tpc44hSXO|YYm= NUPRSHExOTVizszN NXvyXnF3OjUEoHi= M3u0Oolv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= MoLSNlUzPjJ7NkG=
U-87 MG NH3pOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:3NkBp NXrxNmI4UUN3ME2wMlk{KG2PwrC= MV:yOVI1PTN|Mh?=
U-118 MG NIO1[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHrSGxyPzJiaB?= M{K0PGlEPTB;MT6wOUBuVcLi MkfkNlUzPDV|M{K=
U87 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX6NlQhcA>? NYDkNVkxUUN3ME2yOlAvOzRizszNxsA> MXKyOVE4OzJ|Mx?=
U87 GSLCs NXHhOY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fTRVI1KGh? NVTwNoFPUUN3ME23OlYvOTFizszNxsA> NEHXdpQzPTF5M{KzNy=>
U87MG Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTYbmZDPzJiaB?= NVT5SFJvUUN3ME2xOU43OjVizszNxsA> NHPHemozPTB3MEmxOS=>
U251 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjQNFIyODBvNECwJO69VQ>? M1\Bc|Q5KGh? MnPwSG1UVw>? MnzobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYqyOFYzOzd|Nh?=
U87 NHfWbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3QVmQyODBvNECwJO69VQ>? M{ezXVQ5KGh? M2LBfmROW09? Ml7CbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnXSNlQ3OjN5M{[=
MDA-MB-231-br NEL2XGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13yVFAuOTBizszN MoHkOFghcA>? MX\EUXNQ MlXSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWHYN2xFOjR4MkO3N|Y>
HCC-1937 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132blAuOzByIN88US=> NFXNZ|Q1QCCq Moj3SG1UVw>? MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHrSO5kzPDZ{M{ezOi=>
MDA-MB-231 M{ToNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzuU4FOOC12MDFOwG0> NX7Vb4Z7PDhiaB?= NVXWVFY1TE2VTx?= M2jCS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{e5NlI1PjJ|N{O2
MDA-MB-468 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;hVItLOC13MECg{txO NF2yXpA1QCCq M3H2d2ROW09? M{[2XIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYXTTWFiOjR4MkO3N|Y>
T47D NVHUdXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTTUIQxNTFyMDFOwG0> M{XkOlQ5KGh? Mn;tSG1UVw>? MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{HxS|I1PjJ|N{O2
MCF7 NFn3UINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;BdVAuOTByMDFOwG0> NEWwXFc1QCCq Mm\JSG1UVw>? MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MV:yOFYzOzd|Nh?=
Hs683 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofINE0yODByIN88US=> NVS5V|ZpQTZiaB?= NWTiSlBbUUN3ME2xNlgvQSEQvF2= NVn0SFRIOjR2OUW5NFc>
U87 M4HUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMVExODBizszN M2XoOlk3KGh? M17jO2lEPTB;MUiuOFUh|ryP NUfIZW5{OjR2OUW5NFc>
LNZ308 NVzLXYl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSxNE0yODByIN88US=> NWfndYROQTZiaB?= NHq1Nm9KSzVyPUOyOk44KM7:TR?= M3:zRVI1PDl3OUC3
U87 NFjO[FRCeG:ydH;zbZMhSXO|YYm= M4[xdVExOCEQvF2= NEnYWlc1QCCq NHO1eHNFVVOR MXfpcoNz\WG|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7 Ml6wNlQ1QDF3OE[=
U251  MYrBdI9xfG:|aYOgRZN{[Xl? NID0NVYyODBizszN MlLTOFghcA>? MYjEUXNQ Ml[wbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= MVeyOFQ5OTV6Nh?=
U251 NFrHbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfzS4gzPCCq NGjy[4tKSzVyPUi2MlI66oDLwsJihKkyNjV6IN88US=> NGnrbZUzPDN{Nkm1OC=>
U251 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG0PEBp M33oVWlEPTB;N{WuN|TjiIoEsfMAjVEvODJizszN NU\zd3RzOjR|Mk[5OVQ>
U251 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3GW2RNPzJiaB?= NXLDe3NkUUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> NXTDcmZQOjR|Mk[5OVQ>
U251 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe5OkBp MkjLTWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= NGXnSJgzPDN{Nkm1OC=>
T98G NWrBUm1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKwMVc2OCEQvF2= M4PlZVczNzl4IHi= MXvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NXn1cnc5OjR|MkSwPFA>
U251-MG MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHENE05ODBizszN MnnjO|IhcA>? NGrYTXVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkjUNlQxQTN4M{C=
D54-MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonXNE05ODBizszN NYXodY9DPzJiaB?= MVXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2K5e|I1ODl|NkOw
SHG-44 NGXFO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP0cY0yOC1{MECg{txO M3zOXVk3KGh? NFq0XplKSzVyPUmuO|MhyrFiMj6xNkDPxE1? MkT2NlQxPjV3Nkm=
U373  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqyXJUyOC1{MECg{txO NWj0NHpzQTZiaB?= Mne5TWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>? NXfCXZFVOjRyNkW1Olk>
HT-29  NEXPOnlHfW6ldHnvckBCe3OjeR?= M2XKSVUxOCEQvF2= MV:yOE81QCCq M2exZoVvcGGwY3XzJJRp\SCuZY\lcJMhd2ZizsOtTFJCYMLi NIm4PIEzPDB|OEC2PC=>
PC-3  NU[wXmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvVdZcxNTJ3IN88US=> NIXnfnA1QCCq NUi2ZnhucW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJJBwfGWwdHnheIVlKGK7IHz5Z49x\W6n M17TeFI{PzR4OUO0
PC-3  M33jN2Fxd3C2b4Ppd{BCe3OjeR?= MljTNlUh|ryP Mk\YOFghcA>? NWTyPWpRcW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m M4W2TFI{PzR4OUO0
T98G M1\xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i0O|UxNTRyMDFOwG0> MmjrNVQ1KGh? NWW5SGJDcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NXXCXGdqOjN5MUW0PVk>
U87-MG NVTnZY5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e0PVExOCEEtV2= M{nOTVczKGh? M{PUPIlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? M{fEZlI{Pjl4N{i4
U251-MG M1jPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnkNVAxKML3TR?= Ml;yO|IhcA>? M4mx[IlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? NYi4eVB3OjN4OU[3PFg>
LNT-229 NIf5UWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSzMVExOCEQvF2= NUfVV4R6OjRiaB?= NH\rV4xqdmirYnn0d{BkdG:wb3flcolkKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYGyN|Y3PzZ|Mh?=
T98G MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L3NFExNTdyMDFOwG0> MnnQNlQhcA>? MmLmbY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFjhWVgzOzZ4N{[zNi=>
U87  M{PadWZ2dmO2aX;uJGF{e2G7 M2HZTVExOCEEtV2= NYDhbJh2OyCq NXO0ZnRv\WyndnH0[ZMhfGinIHzleoVteyCxZjDwR4hsOSCjbnSgdGNpczJ? MVuyN|Y3PzR4OR?=
HCT116 MlrFSpVv[3Srb36gRZN{[Xl? NYqwOZJPOTByINM1US=> NFXpRno{KGh? NHXGfFFqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= MWiyN|Y3PzR4OR?=
HCT3-6 M1XhbGZ2dmO2aX;uJGF{e2G7 MlTyNVAxKML3TR?= MVizJIg> NEC1NHFqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= MnfWNlM3Pjd2Nkm=
U-87  NWnOTFhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\INlAuPDBizszN M3\lUVEzKGR? M{jySYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUTBWWM{OjN4NEW3Nlk>
U-87  M2PWUGFxd3C2b4Ppd{BCe3OjeR?= NX:zZ49rOC12MDFOwG0> MnnYN{83KGR? Mk\RbY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MWqyN|Y1PTd{OR?=
U-87  M2C3TGZ2dmO2aX;uJGF{e2G7 NXToWoZOOC12MDFOwG0> NV3aN3VSOy94IHS= MljZbY5lfWOnczDheZRweGijZ4mgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NX;lVGM5OjN4NEW3Nlk>
GB-SCC010 NWryW2JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTFb2c1KGR? NEXMe4pKSzVyPUKyOkDPxE1? M3jRW|I{PjF{N{W1
GB-SCC026 NVPmVFRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3scGc1KGR? MULJR|UxRTV|LkGg{txO MWOyN|YyOjd3NR?=
GB-SCC028 NUjxT2hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jXUFQh\A>? M1HO[2lEPTB;MU[3JO69VQ>? MnzaNlM3OTJ5NUW=
U87 NVHKNG56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HSUVQh\A>? MlTETWM2OD12NT6yJO69VQ>? M2\ndlI{PjF{N{W1
U87 stem cell NIXWWIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK0JIQ> M1HLSGlEPTB;Nk[uO{DPxE1? MXqyN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856,TMZ
Smiles CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2
NCT04238819 Not yet recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company October 20 2020 Phase 1
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) September 1 2020 Early Phase 1
NCT04388475 Recruiting Drug: OKN-007|Drug: Temozolomide (TMZ) Recurrent Malignant Glioma|Brain Glioblastoma Oblato Inc. June 12 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID